Turmeric and symptoms after menopause

Hot-flash frequency and overall symptom scores in a study of a curcuminoid blend.

Key points

  • In postmenopausal women, the studied blend reduced hot-flash frequency by about seven per week more than placebo over 12 weeks. For this blend there is a preliminary signal of less frequent hot flashes. [1] See the evidence 1
  • In the same study no advantage of the blend was found for overall quality of life or overall symptom score. The hot-flash result should not be transferred to all menopausal symptoms. [1] See the evidence 1 2

Practical guide

Check the conclusions and whether they apply to your situation.

Hot-flash frequency and overall quality-of-life and symptom scores were measured separately.

Key points

Why these conclusions

Pilot study

Postmenopausal women aged 41–65 took standardized turmeric extract with a curcuminoid blend: four capsules, 1000 mg curcuminoids total daily, or placebo for 12 weeks. Hot-flash frequency decreased about seven per week more with the studied blend. [1]

At week 12, no advantage was found for overall MENQOL quality of life or overall MRS II symptom score. [1]

TGA warns of rare, sometimes severe liver injury from turmeric or curcumin supplements. Risk may be higher with enhanced-absorption supplements or high doses. Stop and seek medical help for jaundice, dark urine or unusual weakness; avoid such supplements with current or past liver disease. [2]

In postmenopausal women, the studied standardized blend reduced hot-flash frequency by about seven per week more than placebo over 12 weeks.

ParameterData
ResultIn postmenopausal women, the studied standardized blend reduced hot-flash frequency by about seven per week more than placebo over 12 weeks. Difference in changes −7.35 hot flashes/week (95% CI −10.29 to −4.41), p<0.001.
Participants40 postmenopausal women aged 41–65, double-blind pilot RCT
FormOral standardized turmeric extract with curcuminoid blend
Dose4 capsules, each 294.12 mg extract with 250 mg curcuminoids; 1000 mg curcuminoids/day
Dose basis4 capsules, each 294.12 mg extract with 250 mg curcuminoids; 1000 mg curcuminoids/day
Comparatorplacebo
Duration12 weeks
Confidence2/4: Precision: Confidence interval allows a change of around one hot flash per day or less. Consistency: No grounds for a separate downgrade. Applicability to the specified group: Measurement directly addresses the stated narrow PICO. Possible publication bias: No specific data for a separate downgrade. Study methods: Retrospective registration, small pilot.
Evidence base1 randomized trial
Sources[1]

At week 12 no advantage of the studied blend over placebo was found for overall MENQOL quality of life.

ParameterData
ResultAt week 12 no advantage of the studied blend over placebo was found for overall MENQOL quality of life. No significant between-group difference at week 12.
ParticipantsThe same 40 postmenopausal women aged 41–65.
FormStandardized turmeric extract, 4 capsules
Dose1000 mg curcuminoids/day
Dose basis1000 mg curcuminoids/day
Comparatorplacebo
Duration12 weeks
Confidence2/4: Precision: Small sample, exact contrast confidence interval not confirmed. Consistency: No grounds for a separate downgrade. Applicability to the specified group: Measurement directly addresses the stated narrow PICO. Possible publication bias: No specific data for a separate downgrade. Study methods: Pilot with retrospective registration and several secondary outcomes.
Evidence base1 randomized trial
Sources[1]

At week 12 no advantage of the studied blend over placebo was found for overall MRS II symptom score.

ParameterData
ResultAt week 12 no advantage of the studied blend over placebo was found for overall MRS II symptom score. No significant between-group difference at week 12.
ParticipantsThe same 40 postmenopausal women aged 41–65.
FormStandardized turmeric extract, 4 capsules
Dose1000 mg curcuminoids/day
Dose basis1000 mg curcuminoids/day
Comparatorplacebo
Duration12 weeks
Confidence2/4: Precision: Small sample, exact contrast confidence interval not confirmed. Consistency: No grounds for a separate downgrade. Applicability to the specified group: Measurement directly addresses the stated narrow PICO. Possible publication bias: No specific data for a separate downgrade. Study methods: Pilot with retrospective registration and several secondary outcomes.
Evidence base1 randomized trial
Sources[1]

TGA warns of rare, sometimes severe liver injury from turmeric or curcumin supplements. Risk may be higher with enhanced-absorption supplements or high doses. Stop and seek medical help for jaundice, dark urine or unusual weakness; avoid such supplements with current or past liver disease.

TGA warns of rare, sometimes severe liver injury from turmeric or curcumin supplements. Risk may be higher with enhanced-absorption supplements or high doses. Stop and seek medical help for jaundice, dark urine or unusual weakness; avoid such supplements with current or past liver disease. [2]

More details

What the result means

The preliminary signal applies to hot-flash frequency in a trial of a specific blend; overall quality-of-life and symptom scores showed no advantage. [1]

Sources

  1. Curcuminoid supplementation for vasomotor symptoms in postmenopausal women: a pilot, randomized, double-blind, placebo-controlled proof-of-concept trial. https://link.springer.com/article/10.1186/s12906-026-05358-7
  2. TGA Medicines containing turmeric or curcumin - risk of liver injury. https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/medicines-containing-turmeric-or-curcumin-risk-liver-injury

Methodology: Subpages evidence-led supplement pipeline v1

Ingredient overview: Curcuma longa